Technology | March 27, 2012

FDA Clears GE Healthcare’s New Class of Angiography Systems

Class offers fixed system image quality and features with versatility of a mobile C-arm

The GE Healthcare Discovery IGS 730 angiography imaging system.

March 26, 2012 – GE Healthcare unveiled two recently U.S. Food and Drug Administration (FDA)-cleared angiography systems offering mobility and advanced imaging for interventional cardiology at the American College of Cardiology's (ACC) 61st Annual Scientific Session in Chicago this week. 

Specifically, GE highlighted its recently FDA-cleared Discovery IGS 730 system, the first interventional X-ray system designed to capture the advantages of both floor- and ceiling-mounted systems, and the mobility of a mobile C-arm. Initially introduced last fall during RSNA 2011, the Discovery system was designed to address the trade-off departments have historically needed to make between ceiling- and floor-mounted systems, eliminating the need to compromise on patient access and image quality. This laser-guided, motorized mobile gantry allows complete access to the patient and unlimited parking capability, while creating sterility for a flexible operating room (OR) environment. The unique gantry comes with a new wide bore design, which allows for steep angles, ease in 3-D acquisition, especially for large patients. 

GE will also introduce the FDA-approved Innova IGS 520/530 with the OR option to expand the use of its Innova imaging system in the hybrid OR setting. With specifically designed table and accessories, the Innova IGS 520/530 OR enables both transcatheter and open surgical procedures in one room.

GE also highlighted its Innova HeartVision solution to help support planning and guidance of structural heart procedures, especially trans-aortic valve replacement (TAVR) procedures. The HeartVision function fuses real time 2-D X-ray images and 3-D models, such as the 3-D cardiac model, from multiple modalities. It can be synchronized with electrocardiogram (ECG) gating and can help compensate for patient heart and respiratory motion throughout the procedure for quality treatment. Innova HeartVision can reduce procedure time and dose, and increase physician confidence by providing the visual tools to make challenging interventions more accessible.

“Interventional cardiology procedures are becoming increasingly complex, and now may be performed in a variety of settings in the hospital, including the operating room. GE Healthcare is revolutionizing cardiac imaging with solutions that adapt to a wider array of environments,” said Reaz Rasul, general manager, interventional cardiology, GE Healthcare - detection and guidance solutions. “With the development of Discovery IGS 730 and Innova IGS 520/530 OR, we are arming physicians with solutions that combine cutting-edge imaging with greater versatility to meet more clinical needs.”

To see a video of the system in operation when it was first unveiled at RSNA 2011, click here.

For more information: www.gehealthcare.com

Related Content

Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and...
Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System
News | Heart Valve Technology | September 05, 2019
Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and effectiveness of its...
An illustration of the BASILICA procedure showing the leaflet of the original bioprosthetic valve sliced open to allow coronary blood flow after implantation of a TAVR valve. The new TAVR valve can push the leaflets of the bioprosthetic valve upwards, blocking the coronary arteries. During the BASILICA procedure, a catheter directs an electrified guidewire through the base of the left aortic cusp into a snare in the left ventricular outflow tract (LVOT). After snare retrieval, the mid-shaft of the guidewire

An illustration of the BASILICA procedure showing the leaflet of the original bioprosthetic valve sliced open to allow coronary blood flow after implantation of a TAVR valve. The new TAVR valve can push the leaflets of the bioprosthetic valve upwards, blocking the coronary arteries. During the BASILICA procedure, a catheter directs an electrified guidewire through the base of the left aortic cusp into a snare in the left ventricular outflow tract (LVOT). After snare retrieval, the mid-shaft of the guidewire is electrified to lacerate the leaflet, and the the leaflet splays after TAVR permitting coronary flow.

Feature | Heart Valve Technology | August 27, 2019
A novel technique has proven successful in preventing coronary artery obstruction during transcatheter aortic valve r
Edwards Recalls Sapien 3 Ultra Delivery System Due to Burst Balloons During Surgery
News | Heart Valve Technology | August 22, 2019
Edwards Lifesciences is recalling the Sapien 3 Ultra delivery system after receiving reports of burst balloons during...
FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

Left, an illustration of the beginning of deployment for a CoreValve Evolut self-expanding transcatheter aortic replacement (TAVR) valve. Right, an illustration of the final balloon expansion of an Edwards Lifesciences Sapien 3 TAVR valve. Both valves received simultaneous FDA clearance for use in low-risk surgical patients. Clearing this last hurdle now allows wide-spread use of minimally invasive TAVR in all patients who otherwise would need an open-heart surgical valve replacement. 

Feature | Heart Valve Technology | August 16, 2019 | Jeff Zagoudis, Associate Editor, and Dave Fornell, Editor
In one coordinated move, the U.S. Food and Drug Administration (FDA) opened transcatheter aortic valve replacement (...
Abbott Receives U.S. Approval of Next-generation MitraClip G4
Technology | Heart Valve Technology | July 17, 2019
Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip heart valve repair...
Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference
News | Heart Valve Technology | July 09, 2019
Neovasc Inc. announced that its Tiara transcatheter mitral valve replacement (TMVR) device and its Neovasc Reducer...
Study Shows Inducing a Heart Attack Helps Valve Patients. This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates some of the tissue in the septum to allow for a larger LVOT area.

This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates (kills) some of the tissue in the cardiac septum to allow these valves to fit better and allow for an enlarged neo-LVOT for patients who otherwise could not receive this therapy. 

News | Heart Valve Technology | July 03, 2019
A study of a procedure developed at Henry Ford Health System shows inducing a heart attack in patients with heart...
CMS Finalizes Updates to Coverage Policy for Transcatheter Aortic Valve Replacement
Feature | Heart Valve Technology | June 24, 2019
The Centers for Medicare and Medicaid Services (CMS) recently finalized its decision to update the national coverage...
Overlay Init